189 related articles for article (PubMed ID: 37871911)
1. SKP2 Knockout in Rb1/p53-Deficient Mouse Models of Osteosarcoma Induces Immune Infiltration and Drives a Transcriptional Program with a Favorable Prognosis.
Ferrena A; Wang J; Zhang R; Karadal-Ferrena B; Al-Hardan W; Singh S; Borjihan H; Schwartz EL; Zhao H; Oktay MH; Yang R; Geller DS; Hoang BH; Zheng D
Mol Cancer Ther; 2024 Feb; 23(2):223-234. PubMed ID: 37871911
[TBL] [Abstract][Full Text] [Related]
2. SKP2 knockout in Rb1/p53 deficient mouse models of osteosarcoma induces immune infiltration and drives a transcriptional program with a favorable prognosis.
Ferrena A; Wang J; Zhang R; Karadal-Ferrena B; Al-Hardan W; Singh S; Borjihan H; Schwartz E; Zhao H; Yang R; Geller D; Hoang B; Zheng D
bioRxiv; 2023 May; ():. PubMed ID: 37214958
[TBL] [Abstract][Full Text] [Related]
3. Targeted inhibition of SCF
Wang J; Ferrena A; Zhang R; Singh S; Viscarret V; Al-Harden W; Aldahamsheh O; Borjihan H; Singla A; Yaguare S; Tingling J; Zi X; Lo Y; Gorlick R; Schwartz EL; Zhao H; Yang R; Geller DS; Zheng D; Hoang BH
Oncogene; 2024 Mar; 43(13):962-975. PubMed ID: 38355807
[TBL] [Abstract][Full Text] [Related]
4. Targeted Inhibition of the E3 Ligase SCF
Zhao H; Iqbal NJ; Sukrithan V; Nicholas C; Xue Y; Yu C; Locker J; Zou J; Schwartz EL; Zhu L
Cancer Res; 2020 Jun; 80(11):2355-2367. PubMed ID: 32265224
[TBL] [Abstract][Full Text] [Related]
5. Deletions of Retinoblastoma 1 (Rb1) and Its Repressing Target S Phase Kinase-associated protein 2 (Skp2) Are Synthetic Lethal in Mouse Embryogenesis.
Zhao H; Wang H; Bauzon F; Lu Z; Fu H; Cui J; Zhu L
J Biol Chem; 2016 May; 291(19):10201-9. PubMed ID: 26966181
[TBL] [Abstract][Full Text] [Related]
6. p27T187A knockin identifies Skp2/Cks1 pocket inhibitors for advanced prostate cancer.
Zhao H; Lu Z; Bauzon F; Fu H; Cui J; Locker J; Zhu L
Oncogene; 2017 Jan; 36(1):60-70. PubMed ID: 27181203
[TBL] [Abstract][Full Text] [Related]
7. Single-cell RNA-seq reveals T cell exhaustion and immune response landscape in osteosarcoma.
Fan Q; Wang Y; Cheng J; Pan B; Zang X; Liu R; Deng Y
Front Immunol; 2024; 15():1362970. PubMed ID: 38629071
[TBL] [Abstract][Full Text] [Related]
8. Skp2 is required for survival of aberrantly proliferating Rb1-deficient cells and for tumorigenesis in Rb1+/- mice.
Wang H; Bauzon F; Ji P; Xu X; Sun D; Locker J; Sellers RS; Nakayama K; Nakayama KI; Cobrinik D; Zhu L
Nat Genet; 2010 Jan; 42(1):83-8. PubMed ID: 19966802
[TBL] [Abstract][Full Text] [Related]
9. Deletion of Trp53 and Rb1 in Ctsk-expressing cells drives osteosarcoma progression by activating glucose metabolism and YAP signaling.
Li Y; Yang S; Liu Y; Yang S
MedComm (2020); 2022 Jun; 3(2):e131. PubMed ID: 35615117
[TBL] [Abstract][Full Text] [Related]
10. A novel signature to guide osteosarcoma prognosis and immune microenvironment: Cuproptosis-related lncRNA.
Yang M; Zheng H; Xu K; Yuan Q; Aihaiti Y; Cai Y; Xu P
Front Immunol; 2022; 13():919231. PubMed ID: 35967366
[TBL] [Abstract][Full Text] [Related]
11. High Skp2 expression characterizes high-risk neuroblastomas independent of MYCN status.
Westermann F; Henrich KO; Wei JS; Lutz W; Fischer M; König R; Wiedemeyer R; Ehemann V; Brors B; Ernestus K; Leuschner I; Benner A; Khan J; Schwab M
Clin Cancer Res; 2007 Aug; 13(16):4695-703. PubMed ID: 17652624
[TBL] [Abstract][Full Text] [Related]
12. Targeting the untargetable: RB1-deficient tumours are vulnerable to Skp2 ubiquitin ligase inhibition.
Gupta P; Zhao H; Hoang B; Schwartz EL
Br J Cancer; 2022 Oct; 127(6):969-975. PubMed ID: 35752713
[TBL] [Abstract][Full Text] [Related]
13. A novel immune cell signature for predicting osteosarcoma prognosis and guiding therapy.
Pan R; Pan F; Zeng Z; Lei S; Yang Y; Yang Y; Hu C; Chen H; Tian X
Front Immunol; 2022; 13():1017120. PubMed ID: 36189307
[TBL] [Abstract][Full Text] [Related]
14. A novel classification predicts prognosis and drug sensitivity in osteosarcoma based on alterations in gene sets.
Ye S; Wang X; Chen R
Aging (Albany NY); 2024 Feb; 16(5):4579-4590. PubMed ID: 38428404
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of Skp2 suppresses the proliferation and invasion of osteosarcoma cells.
Ding L; Li R; Han X; Zhou Y; Zhang H; Cui Y; Wang W; Bai J
Oncol Rep; 2017 Aug; 38(2):933-940. PubMed ID: 28627672
[TBL] [Abstract][Full Text] [Related]
16. EVI2B Is a Prognostic Biomarker and Is Correlated with Monocyte and Macrophage Infiltration in Osteosarcoma Based on an Integrative Analysis.
Dai Z; Liu Z; Yang R; Cao W; Ji T
Biomolecules; 2023 Feb; 13(2):. PubMed ID: 36830696
[TBL] [Abstract][Full Text] [Related]
17. Skp2 overexpression is highly representative of intrinsic biological aggressiveness and independently associated with poor prognosis in primary localized myxofibrosarcomas.
Huang HY; Kang HY; Li CF; Eng HL; Chou SC; Lin CN; Hsiung CY
Clin Cancer Res; 2006 Jan; 12(2):487-98. PubMed ID: 16428491
[TBL] [Abstract][Full Text] [Related]
18. The G1 phase E3 ubiquitin ligase TRUSS that gets deregulated in human cancers is a novel substrate of the S-phase E3 ubiquitin ligase Skp2.
Jamal A; Swarnalatha M; Sultana S; Joshi P; Panda SK; Kumar V
Cell Cycle; 2015; 14(16):2688-700. PubMed ID: 26038816
[TBL] [Abstract][Full Text] [Related]
19. Rb and p53-Deficient Myxofibrosarcoma and Undifferentiated Pleomorphic Sarcoma Require Skp2 for Survival.
Li GZ; Okada T; Kim YM; Agaram NP; Sanchez-Vega F; Shen Y; Tsubokawa N; Rios J; Martin AS; Dickson MA; Qin LX; Socci ND; Singer S
Cancer Res; 2020 Jun; 80(12):2461-2471. PubMed ID: 32161142
[TBL] [Abstract][Full Text] [Related]
20. Skp2 suppresses apoptosis in Rb1-deficient tumours by limiting E2F1 activity.
Lu Z; Bauzon F; Fu H; Cui J; Zhao H; Nakayama K; Nakayama KI; Zhu L
Nat Commun; 2014 Mar; 5():3463. PubMed ID: 24632684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
